The Clinical Trials Program has actively engaged in over 30 investigator initiated and pharmaceutical funded clinical trials phased 2-4. Participants for these trials are recruited to help investigate treatments that focus on a new drug, combination of drugs, or a new strategy for existing therapies. Through these trials, the program contributes invaluable information to the field of medical therapy, influencing research and understanding of new ways to better prevent, detect and understand diabetes around the globe.
We are currently seeking participants with Type 2 diabetes for an active clinical trial: REMIT iGlarLixi. For more information about the trial, including eligibility, please contact Marnie Orcutt.
Our Team is currently running six active studies at our fully-equipped research site, which include: Remit Dapa (Dapagliflozin), Remit iGlarLixi (Lantus-Lixisenatide), RESET IT, DECLARE, PROMISE and PIONEER-8.